Tamoxifen does not improve survival of patients with advanced hepatocellular carcinoma.

To discover whether tamoxifen is able to extend the survival of patients with advanced hepatocellular carcinoma, we included 80 patients with cirrhosis and advanced hepatocellular carcinoma in a multicenter, double-blind, placebo-controlled trial in order to analyze the influence of treatment with tamoxifen on survival. The patients were randomized to receive tamoxifen, 40 mg/day (group 1), or placebo (group 2). Both groups were similar in age, sex, etiology of cirrhosis, biochemical, hematologic and hormonal parameters, morphology of the tumor (nodular vs multinodular or massive), Child-Pugh's score, and Okuda's stage. The 1-year survival rate was similar in both groups (30% in group 1 vs 37.8% in group 2; p = 0.31). Tamoxifen treatment was well tolerated by the patients. We conclude that tamoxifen does not extend the survival of patients with cirrhosis and advanced hepatocellular carcinoma.

[1]  V. Jordan,et al.  Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism , 1995 .

[2]  J. Bruix,et al.  Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. , 1995, Gastroenterology.

[3]  S. Hadziyannis,et al.  Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: A randomized, controlled trial , 1995, Hepatology.

[4]  J. Bruix,et al.  Treatment of small hepatocellular carcinoma in cirrhotic patients: A cohort study comparing surgical resection and percutaneous ethanol injection , 1993, Hepatology.

[5]  H. Bismuth,et al.  Liver Resection Versus Transplantation for Hepatocellular Carcinoma in Cirrhotic Patients , 1993, Annals of surgery.

[6]  S. Kawasaki,et al.  Surgery for small liver cancers. , 1993, Seminars in surgical oncology.

[7]  D. Collins,et al.  Inhibition of angiogenesis by antiestrogens. , 1993, Cancer research.

[8]  K. Okuda,et al.  Hepatocellular carcinoma: Recent progress , 1992, Hepatology.

[9]  D. V. van Thiel,et al.  Hormonal manipulation of human hepatocellular carcinoma. A clinical investigative and therapeutic opportunity. , 1990, Journal of hepatology.

[10]  F. Farinati,et al.  Unresectable hepatocellular carcinoma: a prospective controlled trial with tamoxifen. , 1990, Journal of hepatology.

[11]  B. Levin,et al.  A phase II trial of tamoxifen in hepatocellular carcinoma , 1990, Cancer.

[12]  J. Bruix,et al.  Natural history of hepatocellular carcinoma in Spain. Five year's experience in 249 cases. , 1990, Journal of hepatology.

[13]  K. Goa,et al.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. , 1989, Drugs.

[14]  V. Mazzaferro,et al.  The effect of estrogen and tamoxifen on hepatocyte proliferation in Vivo and in Vitro , 1989, Hepatology.

[15]  A. Forbes,et al.  Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone. , 1987, European journal of cancer & clinical oncology.

[16]  S. Ohnishi,et al.  Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue , 1986, Hepatology.

[17]  H. Hasegawa,et al.  Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients , 1985, Cancer.

[18]  J. Ameriks,et al.  Hepatic cell adenomas, spontaneous liver rupture, and oral contraceptives. , 1975, Archives of surgery.

[19]  J. P. O'sullivan,et al.  Liver Hamartomas in Patients on Oral Contraceptives , 1974, British medical journal.

[20]  R. Pugh,et al.  Transection of the oesophagus for bleeding oesophageal varices , 1973, The British journal of surgery.

[21]  P. Majerus,et al.  Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma. , 1972, Lancet.

[22]  C. Guarner,et al.  Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. , 1994, Journal of hepatology.

[23]  J. Bruix,et al.  Sex hormone receptors in hepatocellular carcinoma , 1993 .

[24]  J. Bruix,et al.  Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? , 1993, Journal of hepatology.

[25]  N. Nagasue,et al.  Estrogen receptors in hepatocellular carcinoma , 1986, Cancer.

[26]  J. Cruz,et al.  Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature. , 1985, Journal of hepatology.

[27]  B. Furr,et al.  The pharmacology and clinical uses of tamoxifen. , 1984, Pharmacology & therapeutics.

[28]  S. Noguchi,et al.  Down‐regulation of transforming growth factor‐α by tamoxifen in human breast cancer , 2022 .